Chylothorax (Thoracic Duct Leak)

Chylothorax is the accumulation of chyle (a milky lymphatic fluid rich in triglycerides absorbed as long-chain fatty acids from intestinal lacteals during digestion) in the pleural space. Anatomy: the thoracic duct is the largest lymphatic vessel in the body, originating at the cisterna chyli (in the abdomen at L1-L2 level), ascending through the aortic hiatus into the right posterior mediastinum, crossing the midline at the T4-T5 level (left of midline above this), and emptying into the left subclavian vein at the venous angle (junction of left subclavian and left internal jugular veins). The thoracic duct carries 1.5-3 liters of chyle daily and drains lymph from the entire body except the right upper extremity, right side of head and neck, and right thoracic structures (which drain into the right lymphatic duct). Disruption or obstruction of the thoracic duct or its tributaries causes chyle to leak into the pleural cavity (right side if disruption below T4-T5, left side if disruption above T4-T5; but variable depending on collateral pathways). Bilateral chylothorax can occur with central duct obstruction.

Etiology categories: (1) Traumatic chylothorax (50-60% of cases): postoperative is the most common cause in modern practice — esophagectomy (1-3% incidence, the most common iatrogenic cause), pulmonary resection especially right pneumonectomy and superior mediastinal dissection (0.5-2%), cardiac surgery (especially CABG and valve surgery, 0.2-0.5%), thoracic aneurysm repair, mediastinal mass resection, lung transplant (4-10%), neck dissection, and central venous catheter insertion (subclavian or internal jugular vein, especially left side). Other traumatic causes: penetrating chest trauma (gunshot, stab, knife wounds), blunt thoracic trauma especially with vertebral fracture or hyperextension injuries, severe vomiting or coughing rarely causes spontaneous rupture (Boerhaave-like syndrome of thoracic duct). (2) Non-traumatic chylothorax (40-50%): malignancy is most common, with lymphoma accounting for 30-40% of malignant cases (Hodgkin and non-Hodgkin lymphoma can compress or invade thoracic duct or mediastinal lymph nodes), followed by lung cancer, esophageal cancer, breast cancer, and metastatic disease. Congenital lymphatic anomalies: pulmonary lymphangioleiomyomatosis (LAM, in women), congenital pulmonary lymphangiectasia, lymphangiomatosis, Noonan syndrome with lymphatic dysplasia, Gorham-Stout syndrome (vanishing bone disease), Down syndrome. Other causes: tuberculosis with mediastinal lymphadenopathy, sarcoidosis, retrosternal goiter, fibrosing mediastinitis (histoplasmosis), hepatic cirrhosis with chylous ascites and hepatic hydrothorax (rare), filariasis (in endemic areas), and idiopathic (10%, often related to subclinical thoracic duct anomalies).

Clinical presentation: depends on volume and rate of accumulation. Acute traumatic chylothorax may produce rapid dyspnea, cough, chest pain, hypotension; chronic accumulation more insidious with progressive dyspnea, fatigue, weight loss, malnutrition, and immunosuppression (chyle contains lymphocytes and immunoglobulins, with 10-20% of body's protein and 20-30% of body's lymphocytes lost daily with chronic chyle drainage). Physical examination: dullness to percussion, decreased breath sounds, decreased fremitus on affected side. Workup: chest radiograph (large pleural effusion), chest CT with contrast (assess malignancy, lymphadenopathy, mediastinal masses, postoperative complications). Diagnostic thoracentesis with pleural fluid analysis is the cornerstone of diagnosis. Pleural fluid characteristics in chylothorax: (1) Gross appearance: milky-white if patient is eating, may be clear or serous if patient is fasting (lipid content depends on intake of long-chain triglycerides). (2) Triglyceride level: over 110 mg/dL (over 1.24 mmol/L) is diagnostic; values 50-110 mg/dL are suggestive and require confirmation with lipoprotein electrophoresis showing chylomicrons (most specific test for chylothorax). (3) Cholesterol typically less than 200 mg/dL (distinguishes from pseudochylothorax/cholesterol pleural effusion which has cholesterol over 200 mg/dL with cholesterol crystals on microscopy). (4) Cell count: lymphocyte predominant (often greater than 80% lymphocytes). (5) Protein and lactate dehydrogenase fit Light criteria for exudate. (6) pH typically alkaline (7.4-7.8). (7) Cultures and Gram stain to rule out infection. Lipoprotein electrophoresis demonstrating chylomicrons is the gold standard if lipid analysis is borderline. Imaging to localize leak: lymphangiography (oily contrast injection into pedal lymphatic, fluoroscopic visualization of duct and leak site, also therapeutic with possible embolization of leak) is gold standard but technically demanding; magnetic resonance lymphangiography (MRL) is non-invasive alternative. Treatment: conservative management is first-line and successful in 50-80% of cases. (1) Dietary modification: strict low-fat diet (less than 10 g/day of long-chain triglycerides) supplemented with medium-chain triglycerides (MCT) which bypass thoracic duct (absorbed directly into portal venous system), reducing chyle production. (2) NPO with total parenteral nutrition (TPN) for severe or refractory cases (eliminates chyle production but not without complications including line infection, hyperglycemia, hepatic dysfunction). (3) Octreotide (somatostatin analog) 50-100 micrograms subcutaneously three times daily (or continuous IV infusion) reduces splanchnic blood flow, intestinal lymph production, and may close fistula; effective in 60-80% of postsurgical chylothorax. (4) Pleural drainage via chest tube to control pleural effusion symptoms and monitor output trend. (5) Pleurodesis (talc, doxycycline, povidone-iodine) for chronic chylothorax not amenable to surgery. (6) Treatment of underlying malignancy (chemotherapy, radiation) often reduces output in malignant chylothorax over weeks. Surgical management for refractory chylothorax (failure of conservative management for 2-4 weeks, output more than 1000-1500 mL/day, malnutrition, immunosuppression): thoracic duct ligation via thoracoscopic (VATS) or open thoracotomy (right-sided supradiaphragmatic ligation in lower mediastinum is most common); pleuroperitoneal shunt as alternative. Percutaneous lymphatic embolization via lymphangiography (Cope/Itkin technique) is minimally invasive alternative with growing evidence of efficacy, increasingly preferred in many centers. Outcome: traumatic chylothorax generally good with appropriate management; malignant chylothorax depends on response of underlying malignancy; congenital chylothorax can be challenging especially in neonates.